🟢 Abcellera Biologics is trading 5% up today after announcing a $28M Vertex collaboration

Abcellera Biologics is trading at $5.56 (5% up) after announcing a new R&D collaboration with Vertex Pharmaceuticals.

• The agreement includes a $28 million upfront payment, providing the company with significant non-dilutive funding to support growth prospects.
• The partnership expands Abcellera’s T-cell engager pipeline, driving positive investor sentiment despite broader weakness in the biotech sector.